DYN240920C22500
- 12.50
- 0.000.00%
Dyne Therapeutics Newsroom
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $50 to $55
Dyne Therapeutics Analyst Ratings
Buy Rating Affirmed Amidst Dose Adjustments and Promising Trial Results for Dyne Therapeutics
Dyne Therapeutics (DYN) Receives a Buy From Stifel Nicolaus
Stifel Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $66
Dyne Therapeutics Analyst Ratings
Guggenheim Maintains Buy on Dyne Therapeutics, Raises Price Target to $50
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $52 to $55
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $50 to $55
Dyne Therapeutics (DYN) Receives a Buy From Piper Sandler
Dyne Therapeutics Price Target Raised to $55.00/Share From $48.00 by HC Wainwright & Co.
Chardan Adjusts Price Target on Dyne Therapeutics to $50 From $42, Maintains Buy Rating
Buy Rating Affirmed for Dyne Therapeutics on Strong Financials and Promising Clinical Data
JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating
JP Morgan Maintains Overweight on Dyne Therapeutics, Raises Price Target to $43
Dyne Therapeutics Analyst Ratings
Dyne Therapeutics Inc: J.P. Morgan raises price target from $25 to $39
Chardan Capital: Maintaining the Dyne Therapeutics (DYN.US) rating, adjusted from buy to buy rating, and adjusted the target price from $31.00 to $42.00.